Edition:
United States

Radius Health Inc (RDUS.OQ)

RDUS.OQ on NASDAQ Stock Exchange Global Market

19.99USD
17 Aug 2018
Change (% chg)

$-1.29 (-6.06%)
Prev Close
$21.28
Open
$21.34
Day's High
$21.60
Day's Low
$19.96
Volume
307,358
Avg. Vol
241,474
52-wk High
$41.14
52-wk Low
$19.96

Chart for

About

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosi... (more)

Overall

Beta: 1.03
Market Cap(Mil.): $909.07
Shares Outstanding(Mil.): 45.48
Dividend: --
Yield (%): --

Financials

  RDUS.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -5.79 -- --
ROI: -100.26 2.89 12.63
ROE: -150.72 1.65 14.82

BRIEF-Radius Health Reports Q1 Loss Per Share Of $1.37

* RADIUS HEALTH REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

May 10 2018

BRIEF-Radius Health Initiates Phase 3 Trial Of Abaloparatide Injection For Male Osteoporosis

* RADIUS HEALTH INITIATES PHASE 3 CLINICAL TRIAL OF ABALOPARATIDE INJECTION FOR THE TREATMENT OF MALE OSTEOPOROSIS Source text for Eikon: Further company coverage:

Mar 30 2018

BRIEF-Radius Health Provides Update On CHMP Opinion For Abaloparatide-SC

* RADIUS HEALTH PROVIDES UPDATE ON CHMP OPINION FOR ABALOPARATIDE-SC

Mar 22 2018

BRIEF-Radius Health Reports Q4 Loss Per Share $1.59

* RADIUS HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

Mar 01 2018

Earnings vs. Estimates